These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 2017069)

  • 61. Improving scheduling and reducing costs of psychotropic drugs for outpatients.
    Marder JE; Dimascio A
    Hosp Community Psychiatry; 1973 Aug; 24(8):556-7. PubMed ID: 4715249
    [No Abstract]   [Full Text] [Related]  

  • 62. The Pharmaceutical Benefits Scheme and implications for paediatric prescribing.
    Sinha Y; Brien JA; Craig JC
    J Paediatr Child Health; 2009 Jun; 45(6):351-7. PubMed ID: 19490409
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Managing multiple medications. Controlling costs. Twenty ways you can beat the high costs of taking multiple medications.
    Roberts SS
    Diabetes Forecast; 2002 Oct; 55(10):105-6. PubMed ID: 14768597
    [No Abstract]   [Full Text] [Related]  

  • 64. [Letter: Prescribing of expensive drugs].
    Fenner O
    MMW Munch Med Wochenschr; 1975 Feb; 117(9):362. PubMed ID: 804648
    [No Abstract]   [Full Text] [Related]  

  • 65. Prescription charges and the evaluation of health policies.
    Smith AJ
    Med J Aust; 1991 Mar; 154(5):303-4. PubMed ID: 2017054
    [No Abstract]   [Full Text] [Related]  

  • 66. Impact of managed care on prescription drug use.
    Weiner JP; Lyles A; Steinwachs DM; Hall KC
    Health Aff (Millwood); 1991; 10(1):140-54. PubMed ID: 2045046
    [No Abstract]   [Full Text] [Related]  

  • 67. LETTER: Charges for pharmaceutical services.
    Freedman GI
    Am J Hosp Pharm; 1975 Apr; 32(4):356. PubMed ID: 1130405
    [No Abstract]   [Full Text] [Related]  

  • 68. Analyzing contrasting approaches to drug services.
    Johnson RE; Campbell WH
    Med Care; 1974 Jan; 12(1):62-74. PubMed ID: 4811403
    [No Abstract]   [Full Text] [Related]  

  • 69. Pharmaceutical drawbacks.
    Meyers D
    Med J Aust; 1979 Apr; 1(8):344. PubMed ID: 449826
    [No Abstract]   [Full Text] [Related]  

  • 70. Generic drugs in Canada.
    Vogel MJ
    CMAJ; 1992 Feb; 146(4):444-5. PubMed ID: 1737304
    [No Abstract]   [Full Text] [Related]  

  • 71. Controlling drug costs.
    Muller C; Stolley PD; Becker MH
    Am J Public Health; 1972 Jun; 62(6):755-6. PubMed ID: 5031997
    [No Abstract]   [Full Text] [Related]  

  • 72. Feedback on prescribing.
    Lancet; 1984 Feb; 1(8372):320-1. PubMed ID: 6141386
    [No Abstract]   [Full Text] [Related]  

  • 73. Psychiatrists and psychotropic drug costs.
    Sider RC; Rubin RR; Fligsten KE
    Compr Psychiatry; 1976; 17(6):723-33. PubMed ID: 991604
    [No Abstract]   [Full Text] [Related]  

  • 74. Generic drugs and the Pharmaceutical Benefits Scheme.
    Duchen DL
    Med J Aust; 1988 Nov; 149(10):567-8. PubMed ID: 3185335
    [No Abstract]   [Full Text] [Related]  

  • 75. Restrictions on NHS prescribing in Australia.
    de Souza D
    Br Med J; 1979 Apr; 1(6169):1018. PubMed ID: 435928
    [No Abstract]   [Full Text] [Related]  

  • 76. Curtailment of prescribing in the National Health Service.
    Lancet; 1984 Nov; 2(8412):1136-7. PubMed ID: 6150189
    [No Abstract]   [Full Text] [Related]  

  • 77. Cutting prescribing costs: learning from Birmingham in 1913.
    Houghton G
    BMJ; 1989 Dec 23-30; 299(6715):1625-8. PubMed ID: 2514944
    [No Abstract]   [Full Text] [Related]  

  • 78. Restrictions on NHS prescribing in Australia.
    Smith T
    Br Med J; 1979 Jan; 1(6156):99-100. PubMed ID: 761010
    [No Abstract]   [Full Text] [Related]  

  • 79. Cost of pharmaceutical benefits.
    Meyers DH
    Med J Aust; 1979 Nov; 2(9):483-4. PubMed ID: 522785
    [No Abstract]   [Full Text] [Related]  

  • 80. How Canada holds down drug costs.
    Douglas V
    Forum (Wash); 1977; 1(2):2-5. PubMed ID: 565320
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.